Decomposition of trimethylgallium on Si(100): Spectroscopic identification of the intermediates von Lee, F., Backman, A.L., Lin, R., Gow, T.R., Masel, R.I.

Volltext

The pyrolysis of trimethylgallium on a heated Si(100) substrate von Gow, T.R., Lin, R., Masel, R.I.

Volltext

Chemically vapor deposited tungsten silicide films using dichlorosilane in a single-wafer reactor : growth, properties, and thermal stability von TELFORD, S. G, EIZENBERG, M, CHANG, M, SINHA, A. K, GOW, T. R

Volltext

The decomposition of trumethylgallium, triethylgallium and trimethylaluminum on Si(100) von Gow, T.R, Lee, F, Lin, R, Backman, A.L, Masel, R.I

Volltext

Decomposition of trimethylgallium on Si(100): Spectroscopic identification of the intermediates von Lee, F., Backman, A.L., Lin, R., Gow, T.R., Masel, R.I.

Volltext

Gate dielectric integrity and reliability in 0.5- mu m CMOS technology von Strong, A.W., Stamper, A.K., Bolam, R.J., Furukawa, T., Gow, C.J., Gow, T.R., Martin, D.W., Mittl, S.W., Nakos, J.S., Pennington, S.L.

Volltext bestellen

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis von Williams, J.I, McLaurin, E.B, Kurata, F.K, Abelson, M.B, Gow, J.A, McNamara, T.R

Volltext

Bepotastine Besilate Ophthalmic Solution 1.5% Produces Strong Clinical Benefit for Ocular Itching Immediately Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of... von Clark, J.C, Williams, J.I, Gomes, P.J, Abelson, M.B, Gow, J.A, McNamara, T.R

Volltext

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom (NOCS) Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Alle... von Gow, J.A, Macejko, T.T, Bergmann, M.T, Meier, E, Abelson, M.B, Williams, J.I, McNamara, T.R

Volltext

BepreveTM 1.5% Provides Clinically Meaningful Reduction in Allergen-Induced Ocular Itching for Subjects in an Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical... von Williams, J.I, Schooley, G.L, Gow, J.A, McNamara, T.R

Volltext

BepreveTM 1.5% Reduces Nasal Congestion for at Least 16 Hours: An Analysis of Integrated Data from Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials von Gow, J.A, Williams, J.I, McNamara, T.R, Gomes, P.J, Abelson, M.B

Volltext

BepreveTM 1.5% Reduces Rhinorrhea for at Least 16 Hours: An Integrated Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials von McNamara, T.R, Williams, J.I, Gow, J.A, Gomes, P.J, Abelson, M.A

Volltext

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis von Torkildsen, G.L, Gomes, P.J, Williams, J.I, Gow, J.A, McNamara, T.R

Volltext

The Ocular Comfort and Safety of the Novel Anti-Histamine Bepotastine Besilate Ophthalmic Solution 1.5% in a Healthy Pediatric Population von Protzko, E.E, Gomes, P.J, Williams, J.I, Gow, J.A, McNamara, T.R

Volltext

Bepreve TM 1.5% Provides Clinically Meaningful Reduction in Allergen-Induced Ocular Itching for Subjects in an Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinica... von Williams, J.I., Schooley, G.L., Gow, J.A., McNamara, T.R.

Volltext

Bepreve TM 1.5% Reduces Nasal Congestion for at Least 16 Hours: An Analysis of Integrated Data from Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials von Gow, J.A., Williams, J.I., McNamara, T.R., Gomes, P.J., Abelson, M.B.

Volltext

Bepreve TM 1.5% Reduces Rhinorrhea for at Least 16 Hours: An Integrated Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials von McNamara, T.R., Williams, J.I., Gow, J.A., Gomes, P.J., Abelson, M.A.

Volltext

Bepotastine Besilate Ophthalmic Solution 1.0% Provides Rapid Relief of Rhinorrhea, Total Non-Ocular Symptoms, Tearing, and Ciliary and Episcleral Hyperemia Following Dosing in a Mu... von Meier, E.J, Macejko, T.T, Bergmann, M.T, MCLaurin, E.B, Kurata, F.K, Gomes, P.J, Williams, J.I, Gow, J.A, McNamara, T.R

Volltext

Bepotastine Besilate Ophthalmic Solution 1.5% for Up to 8 Hours Following Dosing Reduces Total Non-Ocular Symptoms, Rhinorrhea, and Tearing in a Multi-Site Clinical Model of Allerg... von Macejko, T.T, Meier, E.J, Bergmann, M.T, McLaurin, E.B, Kurata, F.K, Gomes, P.J, Williams, J.I, Gow, J.A, McNamara, T.R

Volltext